Drug Trial Radar · NCT04404595
Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers
Last checked: Nov 19, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Oct 23, 2020
Primary completion
Jun 1, 2025
Study completion Sep 1, 2035
Sponsor
- Lead sponsor
- CARsgen Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 76 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers
Conditions
- Gastric Cancer
- Pancreatic Cancer
Interventions
CT041Biological
treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b (Cohort A): Evaluate the safety and tolerability of CAR-CLDN18.2 T-cell therapy (CT041) in subjects with specified advanced digestive system cancers (STAD, PAAD, or BTC).Time frame: up to year 15
- Phase 1b (Cohort A): Identify the recommended Phase 2 dose (RP2D) of CT041 therapy in subjects with advanced STAD, PAAD, or BTC.Time frame: day 0 - day 28
- Phase 1b (Cohort A): Identify the maximum tolerated dose (MTD) or maximum administered dose (MAD) of CT041 therapy in subjects with STAD, PAAD, or BTC.Time frame: day 0 - day 28
- Phase 1b (Cohort B): Determine the efficacy of CT041 by ORR in subjects with advanced STAD, PAAD, or BTC.Time frame: up to year 15
- Phase 2 (Cohort C): Determine the efficacy of CT041 by ORR in subjects with advanced STAD treated at the RP2D.Time frame: up to year 15
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
University of Southern California
Los Angeles, California
UCSD
San Diego, California
UCSF
San Francisco, California
Moffitt Cancer Center
Tampa, Florida
University of Kansas Cancer Center
Kansas City, Kansas
Karmanos Cancer Center
Detroit, Michigan
Mayo Cancer Hospital
Rochester, Minnesota
Northwell Cancer Institute
New Hyde Park, New York
The Mount Sinai Hospital
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Ohio State University
Columbus, Ohio
TX Oncology-Baylor Charles Sammons Cancer Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Princess Margaret Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.